LIMCH1

Across TCGA pan-cancer cohorts, LIMCH1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LIMCH1 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LIMCH1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LIMCH1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where LIMCH1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.448	0.972	<.001	21	view →
CCRCC	DFS	Quartile	III,IV	0.857	0.249	.006	20	view →
LUAD	DFS	Quartile	All	0.827	0.996	.003	6	view →
GBM	DFS	Tertile	All	0.502	0.270	.012	4	view →
HNSC	OS	Median	II,III,IV	0.933	0.992	.024	4	view →
LSCC	DFS	Quartile	II,III,IV	0.839	1.000	.032	4	view →
UCEC	DFS	Tertile	All	1.000	0.923	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LIMCH1–PDAC (OS)

Open the PDAC breakdown →